MentalAId: an improved DenseNet model to assist scalable psychosis assessment.

Publication date: Jul 30, 2025

The escalating mental health crisis during and post-COVID-19 underscores the urgent need for scalable, timely, cost-effective assessment solutions for general psychotic disorders. Regretfully, traditional symptom-based, one-to-one assessment face inherent limitations in large-scale and longitudinal screening, likely delaying early intervention. We developed MentalAId, an improved densely connected convolutional network (DenseNet) model, to assist automated psychosis recognition, leveraging accessible routine laboratory data without requiring additional specialized tests. MentalAId learned subtle variations in 49 routine clinical hematological tests and two demographic variables (sex and age) across 28,746 individuals spanning four distinct cohorts: psychotic inpatients (n = 9,271), non-psychotic inpatients with various diseases (n = 14,508), healthy controls (n = 1,826), and drug-nacEFve first-episode psychosis (FEP) patients (n = 3,141). The MentalAId model achieved high accuracy in generally discriminating psychoses from both healthy individuals and patients with other physical diseases, achieving 93. 3% accuracy and AUC of 0. 983. Further validating its robustness, MentalAId demonstrated high performance under real-world clinical conditions, accurately handling extreme values and missing values, with accuracies of 92. 4% and 92. 0%, respectively. Even encompassing the drug-nacEFve FEPs, MentalAId maintained an accuracy of 91. 9%, underscoring its translational potential for early FEP recognition. Interpretability analyses identified indirect bilirubin, direct bilirubin, and basophil ratio as potential metabolic indicators. Collectively, MentalAId offers an accessible, affordable, and scalable solution to assist timely psychosis assessment and monitoring, irrespective of the complexity of pathology or manifestation of symptoms. By requiring standard blood tests solely, it can be easily integrated into existing healthcare workflow. This empowers long-term and population-wide monitoring of disease progression and prognosis, particularly during public health crises like COVID-19.

Open Access PDF

Concepts Keywords
Affordable Adult
Psychiatry Blood test
Workflow Convolutional Neural Networks
COVID-19
Deep learning
Female
First-episode psychosis
Hematological characteristics
Humans
Male
Middle Aged
Neural Networks, Computer
Psychosis diagnosis
Psychotic Disorders
Young Adult

Semantics

Type Source Name
disease MESH psychosis
disease MESH COVID-19
disease IDO symptom
disease IDO intervention
disease IDO blood
disease MESH disease progression
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH neurological disorders
disease MESH psychiatric disorders
disease MESH emotional disturbance
drug DRUGBANK Trestolone
disease MESH relapse
disease MESH depression
disease MESH anxiety
drug DRUGBANK Dopamine
disease MESH schizophrenia
drug DRUGBANK Hydrocortisone
disease MESH bipolar disorder
drug DRUGBANK Cholesterol
drug DRUGBANK Indoleacetic acid
pathway REACTOME Immune System
disease IDO algorithm
disease IDO process
drug DRUGBANK Flunarizine
drug DRUGBANK Cytidine-5′-Monophosphate
drug DRUGBANK Pidolic Acid
drug DRUGBANK Saquinavir
disease IDO history
disease MESH complications
disease MESH metabolic diseases
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK MCC

Original Article

(Visited 4 times, 1 visits today)